Publication:

The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism

Loading...
Thumbnail Image

Date

2009

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Oxford University Press
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Khalpey, Zain, Matthew A. Nehs, Andrew W. ElBardissi, Marcus Semel, and Stefan G. Tullius. 2009. “The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism.” NDT Plus 3 (1): 68-70. doi:10.1093/ndtplus/sfp120. http://dx.doi.org/10.1093/ndtplus/sfp120.

Abstract

A 43-year-old African American with end-stage renal disease (ESRD) associated with membranous nephropathy and a previously failed renal transplant had received cinacalcet to treat his secondary hyperparathyroidism. Serum calcium and phosphorus levels remained within normal limits, and serum parathyroid levels had dropped significantly following treatment initiation. However, within 7 months, the patient experienced extensive necrotic bilateral medial thigh ulcers. These were biopsied and found to be a result of calciphylaxis. The patient ultimately required an urgent subtotal parathyroidectomy and recovered well with completely healed ulcers.

Description

Research Data

Keywords

calciphylaxis, cinacalcet, hyperparathyroidism, sensipar

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories